RecruitingNCT00568490

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

Sponsor

Stanford University

Enrollment

200 participants

Start Date

Sep 1, 1998

Study Type

OBSERVATIONAL

Conditions

Lung Cancer Head and Neck Cancer Lip Cancer Head and Neck Cancers Lip Neoplasms

Summary

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking for blood-based markers that indicate when a tumor has low oxygen levels (hypoxia), which makes some cancers more aggressive and harder to treat — the goal is to develop a simple blood test to guide treatment decisions. **You may be eligible if...** - You have been diagnosed with cancer (specific types as defined by the study) - You are scheduled for imaging or biopsy procedures that can measure tumor oxygen levels - You are willing to provide blood samples alongside your standard care **You may NOT be eligible if...** - You are unable or unwilling to provide informed consent - You have a blood disorder that makes sample collection unsafe - You are not receiving care at a participating institution Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURETumor biopsy

For patients who undergo tumor biopsy or resection at Stanford, approximately 500 mg of the tumor will be removed from the resection specimen

PROCEDUREPhlebotomy

Blood draw (approximately 20 cc) prior to any anticancer therapy Weekly blood draw (approximately 20cc) only for patients who are undergoing radiation treatment at Stanford University